Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + platinum-based chemotherapy + etoposide + aspirin
- Development stage
- Phase 2
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen is being investigated by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of the PD-1 inhibitor serplulimab (Hansizhuang), platinum-based chemotherapy (cisplatin or carboplatin), etoposide, and low-dose aspirin. Serplulimab functions as an immune checkpoint inhibitor by blocking the PD-1/PD-L1 pathway to restore anti-tumor T-cell activity. The chemotherapy components, platinum and etoposide, provide cytotoxic effects by inducing DNA damage and inhibiting topoisomerase II. Aspirin is integrated into the regimen to potentially enhance the anti-tumor efficacy of the immunotherapy by modulating the inflammatory tumor microenvironment through cyclooxygenase (COX) inhibition and reducing treatment-related adverse events such as thrombosis and fever.
- Other names
- Serplulimab + Chemotherapy + Aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on serplulimab + platinum-based chemotherapy + etoposide + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + platinum-based chemotherapy + etoposide + aspirin.